Literature DB >> 21881980

Drug-induced lupus in anti-TNF-alpha therapy and its treatment with rituximab.

Juan C Diaz1, Santiago Vallejo, Carlos A Cañas.   

Abstract

We report three patients with rheumatoid arthritis (RA) who were treated with anti-TNF-α agents and who developed drug-induced lupus (DIL). Two of them received etanercept and the remainder adalimumab. We also present the favorable response observed with the withdrawal of the anti-TNF-alpha agents and the introduction of rituximab. Through this intervention, we observed a very good control of the activity of both DIL and RA without additional adverse reactions.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21881980     DOI： 10.1007/s00296-011-2137-y

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  7 in total

1.  BAFF overexpression is associated with autoantibody production in autoimmune diseases.

Authors:  Jacques-Olivier Pers; Capucine Daridon; Valérie Devauchelle; Sandrine Jousse; Alain Saraux; Christophe Jamin; Pierre Youinou
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

2.  Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity.

Authors:  A P Cairns; A D Crockard; J R McConnell; P A Courtney; A L Bell
Journal:  Ann Rheum Dis       Date:  2001-10       Impact factor: 19.103

Review 3.  Tumour necrosis factor inhibitors.

Authors:  Peter T Nash; Timothy H J Florin
Journal:  Med J Aust       Date:  2005-08-15       Impact factor: 7.738

Review 4.  The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.

Authors:  Marc C Hochberg; Mark G Lebwohl; Scott E Plevy; Kathryn F Hobbs; David E Yocum
Journal:  Semin Arthritis Rheum       Date:  2005-06       Impact factor: 5.532

Review 5.  Lessons for lupus from tumour necrosis factor blockade.

Authors:  M De Bandt
Journal:  Lupus       Date:  2006       Impact factor: 2.911

Review 6.  Anti-TNF-induced lupus.

Authors:  Emma L Williams; Stephan Gadola; Christopher J Edwards
Journal:  Rheumatology (Oxford)       Date:  2009-05-04       Impact factor: 7.580

7.  BAFF and MyD88 signals promote a lupuslike disease independent of T cells.

Authors:  Joanna R Groom; Carrie A Fletcher; Stacey N Walters; Shane T Grey; Sally V Watt; Mathew J Sweet; Mark J Smyth; Charles R Mackay; Fabienne Mackay
Journal:  J Exp Med       Date:  2007-07-30       Impact factor: 14.307
  7 in total
  5 in total

Review 1.  A comprehensive review of rituximab therapy in rheumatoid arthritis patients.

Authors:  Soheil Tavakolpour; Samira Alesaeidi; Mohammad Darvishi; Mojtaba GhasemiAdl; Sahar Darabi-Monadi; Meisam Akhlaghdoust; Somayeh Elikaei Behjati; Arash Jafarieh
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

2.  A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept.

Authors:  Özgür Akgül; Gamze Kılıç; Erkan Kılıç; İsa Cüce; Salih Özgöçmen
Journal:  Rheumatol Int       Date:  2012-12-22       Impact factor: 2.631

Review 3.  New therapeutic strategies in systemic lupus erythematosus management.

Authors:  Mariele Gatto; Margherita Zen; Luca Iaccarino; Andrea Doria
Journal:  Nat Rev Rheumatol       Date:  2019-01       Impact factor: 20.543

4.  Early instauration granulomatous pneumonitis associated with use of etanercept in seronegative spondyloarthropathy: Case report.

Authors:  Liliana Fernández-Trujillo; María B Iriarte; Germán Puerta; Eliana I Morales; Luz F Sua; Carlos A Cañas
Journal:  Respir Med Case Rep       Date:  2020-05-18

5.  Developing of Granulomatosis with Polyangiitis during Etanercept Therapy.

Authors:  María Clara Ortiz-Sierra; Andrés Felipe Echeverri; Gabriel J Tobón; Carlos Alberto Cañas
Journal:  Case Rep Rheumatol       Date:  2014-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.